From: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Parameter | Value |
---|---|
Age (years) | 57.13 ± 9.21 |
Female/male | 24/6 |
Duration of disease (years) | 9.43 ± 8.97 |
Number of of tender joints | 16.46 ± 9.1 |
Number of swollen joints | 6.83 ± 4.814 |
RF positivity | 86.70% |
Joint erosions | 100% |
Serum CRP (mg/dl) | 3.85 ± 2.74 |
DAS 28 | 6.1 ± 1.025 |
HAQ | 1.78 ± 0.422 |
Previous DMARDs | |
   Methotrexate | 30 |
   Hydroxycloroquine | 26 |
   Sulfasalazine | 18 |
   Cyclosporin A | 19 |
   Gold (intramuscular) | 3 |
   Leflunomide | 1 |
   Azathioprine | 1 |